Oisin N. Kavanagh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Oisin N. Kavanagh has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Gavin M. Walker
Department of Chemical Sciences, University of Limerick, Limerick, Ireland
6 shared publications Kimberley A. Noble
School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK
3 shared publications- Parag Roy
School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK
3 shared publications - Tatiane Cogo Machado
School of Mathematical and Physical Sciences, Faculty of Science, University of Technology Sydney, Australia
3 shared publications - Ahmad B. Albadarin
Pharmaceutical & Chemical Engineering, German Jordanian University, Amman, Jordan
2 shared publications - Denise M. Croker
Synthesis and Solid State Pharmaceutical Centre (SSPC), Bernal Institute, University of Limerick, Limerick, Ireland
2 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Springer Nature in Research Square
Revisiting amoxicillin prophylaxis for infective endocarditis: a pharmacokinetic and cost-effectiveness analysis
Introduction The role of antibiotic prophylaxis in preventing infective endocarditis has long been contentious, and recent changes to United Kingdom guidance now recommend prophylaxis for patients at high risk undergoing invasive dental procedures. Comparatively little attention has been directed towards optimisation of the prophylactic amoxicillin regimen itself. This study evaluated the pharmacokinetic and economic rationale underpinning contemporary dental amoxicillin prophylaxis. Methods National Health Service dental prescribing data and Drug Tariff pricing information were analysed to characterise amoxicillin prescribing patterns and costs. Published pharmacokinetic studies were reviewed to examine the relationship between amoxicillin dose, bioavailability, and systemic exposure. A model was developed to compare exposure achieved by conventional prophylactic regimens and alternative divided-dose strategies. A previously published cost-effectiveness model was rebuilt as a cost-utility analysis using contemporary amoxicillin pricing, pooled efficacy estimates from a recent meta-analysis, and updated estimates of infective endocarditis incidence following invasive dental procedures. Incremental costs, quality-adjusted life years (QALYs) and threshold acquisition costs were calculated, with deterministic and probabilistic sensitivity analyses. Results Amoxicillin remained one of the most prescribed antibiotics in dentistry, accounting for approximately 40% of dental prescribing. Published pharmacokinetic studies demonstrated dose-dependent absorption, with bioavailability declining at higher oral doses. Simulations showed that repeated 500 mg doses administered every 6 hours achieved comparable pharmacodynamic target attainment to conventional 3 g prophylactic regimens despite substantially lower individual doses. The cost of 3 g amoxicillin sachets increased markedly over the study period, producing an approximately 57-fold to 114-fold difference in the cost of a prophylactic course compared with 500 mg capsules, depending on whether a single sachet or a dispensed pack of two was costed. Cost-utility analysis indicated that prophylaxis remained cost-effective in high-risk patients under every costing and formulation examined, with an incremental cost-effectiveness ratio of £140 per QALY for the 3 g sachet and dominance for capsule-based regimens in every group examined. Conclusions Current high-dose amoxicillin prophylaxis regimens may be pharmacokinetically inefficient because of dose-dependent absorption. Lower-dose divided regimens achieved comparable simulated pharmacodynamic exposure at substantially lower cost. Formulation choice, rather than dose, determined whether prophylaxis remained cost-saving. Prospective clinical studies are required to determine whether the pharmacokinetic advantages of lower-dose regimens translate into improved clinical outcomes.
- 25 September 2026
- Published by Springer Nature in Research Square
Open AccessRevisiting amoxicillin prophylaxis for infective endocarditis: a pharmacokinetic and cost-effectiveness analysis
Introduction The role of antibiotic prophylaxis in preventing infective endocarditis has long been contentious, and recent changes to United Kingdom guidance now recommend prophylaxis for patients at high risk undergoing invasive dental procedures. Comparatively little attention has been directed towards optimisation of the prophylactic amoxicillin regimen itself. This study evaluated the pharmacokinetic and economic rationale underpinning contemporary dental amoxicillin prophylaxis. Methods National Health Service dental prescribing data and Drug Tariff pricing information were analysed to characterise amoxicillin prescribing patterns and costs. Published pharmacokinetic studies were reviewed to examine the relationship between amoxicillin dose, bioavailability, and systemic exposure. A model was developed to compare exposure achieved by conventional prophylactic regimens and alternative divided-dose strategies. A previously published cost-effectiveness model was rebuilt as a cost-utility analysis using contemporary amoxicillin pricing, pooled efficacy estimates from a recent meta-analysis, and updated estimates of infective endocarditis incidence following invasive dental procedures. Incremental costs, quality-adjusted life years (QALYs) and threshold acquisition costs were calculated, with deterministic and probabilistic sensitivity analyses. Results Amoxicillin remained one of the most prescribed antibiotics in dentistry, accounting for approximately 40% of dental prescribing. Published pharmacokinetic studies demonstrated dose-dependent absorption, with bioavailability declining at higher oral doses. Simulations showed that repeated 500 mg doses administered every 6 hours achieved comparable pharmacodynamic target attainment to conventional 3 g prophylactic regimens despite substantially lower individual doses. The cost of 3 g amoxicillin sachets increased markedly over the study period, producing an approximately 57-fold to 114-fold difference in the cost of a prophylactic course compared with 500 mg capsules, depending on whether a single sachet or a dispensed pack of two was costed. Cost-utility analysis indicated that prophylaxis remained cost-effective in high-risk patients under every costing and formulation examined, with an incremental cost-effectiveness ratio of £140 per QALY for the 3 g sachet and dominance for capsule-based regimens in every group examined. Conclusions Current high-dose amoxicillin prophylaxis regimens may be pharmacokinetically inefficient because of dose-dependent absorption. Lower-dose divided regimens achieved comparable simulated pharmacodynamic exposure at substantially lower cost. Formulation choice, rather than dose, determined whether prophylaxis remained cost-saving. Prospective clinical studies are required to determine whether the pharmacokinetic advantages of lower-dose regimens translate into improved clinical outcomes.
- Open Access
Investigating 24-Hour Urine Expected Ranges of Non-Kidney Stone Formers: an EAU Endourology Research Group Systematic Review and Meta-Analysis
Background and Objective: There is substantial variation in reference ranges for 24-hour urine collections, leading to diagnostic uncertainty. We aimed to curate robust evidence for expected ranges of 24-hour urine collections in the non-kidney stone forming population. Methods: We performed a systematic review (PROSPERO ID: CRD42024590784) of healthy adults without kidney stone disease undergoing 24-hour urine collections. Each component was meta-analysed in R, stratified by age, sex and ancestry, meta-regression and sensitivity analyses for study design, collection completeness and bias. An explicit eight-branch decision framework selected the recommended analysis per component. Expected ranges were derived from the pooled SD (95% interval); evidence was quantified by GRADE. Key Findings and Limitations: Seventy-two articles were included (10,284 participants). Expected ranges (mmol / 24 h unless stated): volume 1.0–2.5L, calcium 1.9–6.2, oxalate 0.2–0.6 (men) / 0.2–0.4 (women), urate 2.0–5.1(men)/2.3–3.5(women), pH 5.6–6.3, citrate 1.2–4.5, creatinine 12.2– 16.3(men)/7.2–12.6(women), phosphate 19–26, sodium 98–253, potassium 28–77, magnesium 3.1–4.8, ammonium 28–46(men)/20–40(women), chloride 84–218, sulphate 17–26(men)/7–30(women), urea 234–445. Principal limitations were: high between-study heterogeneity (I 2 >95% for most components) and assay/laboratory variability (most marked for citrate and potassium). Conclusions and Clinical Implications: This is the first study to attempt a robust characterization of 24-hour urine expected ranges using meta-analysis. Six of the derived expected ranges (pH, oxalate, magnesium, sulphate, urate, creatinine) were broadly concordant with existing reference ranges, providing an evidence base for those specific components. Take Home Message: This study establishes expected 24-hour urine values in a non-stone-forming population and provides empirical support for the derivation of reference ranges for several common urine analytes. I t also provides a repository of data for further analyses. Patient summary: The existing 24-hour urine reference ranges are poorly characterised. These are important as they are used by clinicians to diagnose and guide treatment for conditions predisposing to kidney stone formation. We have robustly determined expected ranges for people without kidney stones after reviewing existing studies in more than 10,000 people. For several urine components the available data remain limited, and our ranges should be revisited as more evidence accumulates.
Open AccessInvestigating 24-Hour Urine Expected Ranges of Non-Kidney Stone Formers: an EAU Endourology Research Group Systematic Review and Meta-Analysis
Background and Objective: There is substantial variation in reference ranges for 24-hour urine collections, leading to diagnostic uncertainty. We aimed to curate robust evidence for expected ranges of 24-hour urine collections in the non-kidney stone forming population. Methods: We performed a systematic review (PROSPERO ID: CRD42024590784) of healthy adults without kidney stone disease undergoing 24-hour urine collections. Each component was meta-analysed in R, stratified by age, sex and ancestry, meta-regression and sensitivity analyses for study design, collection completeness and bias. An explicit eight-branch decision framework selected the recommended analysis per component. Expected ranges were derived from the pooled SD (95% interval); evidence was quantified by GRADE. Key Findings and Limitations: Seventy-two articles were included (10,284 participants). Expected ranges (mmol / 24 h unless stated): volume 1.0–2.5L, calcium 1.9–6.2, oxalate 0.2–0.6 (men) / 0.2–0.4 (women), urate 2.0–5.1(men)/2.3–3.5(women), pH 5.6–6.3, citrate 1.2–4.5, creatinine 12.2– 16.3(men)/7.2–12.6(women), phosphate 19–26, sodium 98–253, potassium 28–77, magnesium 3.1–4.8, ammonium 28–46(men)/20–40(women), chloride 84–218, sulphate 17–26(men)/7–30(women), urea 234–445. Principal limitations were: high between-study heterogeneity (I 2 >95% for most components) and assay/laboratory variability (most marked for citrate and potassium). Conclusions and Clinical Implications: This is the first study to attempt a robust characterization of 24-hour urine expected ranges using meta-analysis. Six of the derived expected ranges (pH, oxalate, magnesium, sulphate, urate, creatinine) were broadly concordant with existing reference ranges, providing an evidence base for those specific components. Take Home Message: This study establishes expected 24-hour urine values in a non-stone-forming population and provides empirical support for the derivation of reference ranges for several common urine analytes. I t also provides a repository of data for further analyses. Patient summary: The existing 24-hour urine reference ranges are poorly characterised. These are important as they are used by clinicians to diagnose and guide treatment for conditions predisposing to kidney stone formation. We have robustly determined expected ranges for people without kidney stones after reviewing existing studies in more than 10,000 people. For several urine components the available data remain limited, and our ranges should be revisited as more evidence accumulates.
- Open Access
- 11 August 2026
- Published by Elsevier in Human Factors in Healthcare
- Vol. 10
Safety Culture in Community Pharmacies: a cross-sectional study using the Community Pharmacy Survey on Patient Safety Culture
- 11 August 2026
- Published by Elsevier in Human Factors in Healthcare
- Vol. 10
Open AccessSafety Culture in Community Pharmacies: a cross-sectional study using the Community Pharmacy Survey on Patient Safety Culture
- 23 June 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (10) , 4787-4788
Voices in Molecular Pharmaceutics: Meet Dr. Oisín Kavanagh, Who Manipulates Crystal Packing to Improve Drug Delivery
- 23 June 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (10) , 4787-4788
Voices in Molecular Pharmaceutics: Meet Dr. Oisín Kavanagh, Who Manipulates Crystal Packing to Improve Drug Delivery
- Open Access
- 27 April 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (7) , 3753-3759
Precipitation Inhibition by Small-Molecule Analogues To Sustain Drug Supersaturation
Maintaining supersaturation during gastric-to-intestinal pH transitions can be essential to maximize the oral exposure of pH-sensitive drugs. This study demonstrates a mechanistically guided strategy to stabilize ciprofloxacin supersaturation using structurally related fluoroquinolone analogues as nucleation inhibitors. Structural similarity screening identified danofloxacin and levofloxacin as promising candidates, and their effects were evaluated using nucleation induction time, dynamic pH-shift dissolution, and 1H NMR spectroscopy. Danofloxacin produced the most significant extension of nucleation induction time and was superior to classical polymeric precipitation inhibitors (hypromellose and polyvinylpyrrolidone). During pH-shift dissolution, ciprofloxacin alone retained only ∼20% of its initial concentration after 30 min at pH 7.0, whereas danofloxacin and levofloxacin sustained ∼92% and ∼37%, respectively. Correspondingly, AUC0–240 min increased by 5.44-fold for danofloxacin and 1.65-fold for levofloxacin, with HPMC and PVP providing 2.8-fold and 1.25-fold increases. 1H NMR revealed concentration-dependent aromatic shielding consistent with ciprofloxacin···analogue heteroassociation, with danofloxacin producing the most substantial and most symmetric perturbations. These data sets support a kinetic mechanism in which isostructural analogues disrupt ciprofloxacin self-association, delay the formation of prenucleation aggregates, and prolong supersaturation. The findings establish small-molecule structural mimicry as a viable pathway for stabilizing supersaturation and guiding mechanism-based coformulation design.
- 27 April 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (7) , 3753-3759
Open AccessPrecipitation Inhibition by Small-Molecule Analogues To Sustain Drug Supersaturation
Maintaining supersaturation during gastric-to-intestinal pH transitions can be essential to maximize the oral exposure of pH-sensitive drugs. This study demonstrates a mechanistically guided strategy to stabilize ciprofloxacin supersaturation using structurally related fluoroquinolone analogues as nucleation inhibitors. Structural similarity screening identified danofloxacin and levofloxacin as promising candidates, and their effects were evaluated using nucleation induction time, dynamic pH-shift dissolution, and 1H NMR spectroscopy. Danofloxacin produced the most significant extension of nucleation induction time and was superior to classical polymeric precipitation inhibitors (hypromellose and polyvinylpyrrolidone). During pH-shift dissolution, ciprofloxacin alone retained only ∼20% of its initial concentration after 30 min at pH 7.0, whereas danofloxacin and levofloxacin sustained ∼92% and ∼37%, respectively. Correspondingly, AUC0–240 min increased by 5.44-fold for danofloxacin and 1.65-fold for levofloxacin, with HPMC and PVP providing 2.8-fold and 1.25-fold increases. 1H NMR revealed concentration-dependent aromatic shielding consistent with ciprofloxacin···analogue heteroassociation, with danofloxacin producing the most substantial and most symmetric perturbations. These data sets support a kinetic mechanism in which isostructural analogues disrupt ciprofloxacin self-association, delay the formation of prenucleation aggregates, and prolong supersaturation. The findings establish small-molecule structural mimicry as a viable pathway for stabilizing supersaturation and guiding mechanism-based coformulation design.
- Open Access
- 22 April 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
A rapid HPLC method to simultaneously quantify therapeutic thiols and monitor their disulfide exchange reactions with cystine
This study introduces a rapid and environmentally sustainable High Performance Liquid Chromatography method to simultaneously quantify free thiols and moni
- 22 April 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Open AccessA rapid HPLC method to simultaneously quantify therapeutic thiols and monitor their disulfide exchange reactions with cystine
This study introduces a rapid and environmentally sustainable High Performance Liquid Chromatography method to simultaneously quantify free thiols and moni
- Open Access
- 11 March 2026
- Published by Elsevier in SSRN Electronic Journal
BIPOLITH: 7Li-MRI Brain Lithium Temporospatial Kinetics across the Day with Once Versus Twice Daily Regimens in Bipolar Disorder
Background: Lithium remains a first-line treatment for bipolar disorder, but practice varies regarding dosing frequency. Once-daily and twice-daily regimens are comparably effective, but side-effect profiles may differ. Serum lithium profiles over the day differ between regimens but it is unclear whether the greater fluctuations with once daily dosing are attenuated in the brain. Understanding the brain pharmacokinetics of lithium across regimens could refine therapeutic monitoring and guide choices that might mitigate long-term adverse effects.Methods: In this cross-sectional imaging study, 41 euthymic individuals with bipolar disorder receiving stable lithium carbonate treatment (20 once-daily, 21 twice-daily) underwent three consecutive 7Li-MRI scans and matched serum sampling over a 10-hour period (08:00, 14:00, and 18:00h). Whole brain lithium measurements across time points were compared according to regimen. Secondary analyses modelled tissue-specific profiles and examined the relationship between serum and brain lithium concentration using repeated measures ANOVA, linear mixed-effects models and population pharmacokinetics.Findings: At 12-hours post-dose (08:00h), brain lithium signal intensity and serum concentrations were equivalent across regimens. However, brain and serum lithium profiles differed over the daytime sampling period: once-daily dosing yielded declining serum and brain levels, while twice-daily dosing produced an inverted U-shaped serum and brain profile. Brain lithium signal intensity was higher in white matter than grey matter in both regimens and brain–serum ratios indicated more rapid equilibration in grey matter and cerebrospinal fluid compared to white matter. Interpretation: Brain lithium levels followed serum concentrations closely across the day, but aligned between regimens at the standard 12-hour post-dose sampling time point. These findings directly inform the ongoing discussion about the applicability of a common reference range across regimens. The difference in brain and serum profiles of lithium with once- and twice-daily dosing may inform regimen selection and therapeutic monitoring strategies in clinical practice.
- 11 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBIPOLITH: 7Li-MRI Brain Lithium Temporospatial Kinetics across the Day with Once Versus Twice Daily Regimens in Bipolar Disorder
Background: Lithium remains a first-line treatment for bipolar disorder, but practice varies regarding dosing frequency. Once-daily and twice-daily regimens are comparably effective, but side-effect profiles may differ. Serum lithium profiles over the day differ between regimens but it is unclear whether the greater fluctuations with once daily dosing are attenuated in the brain. Understanding the brain pharmacokinetics of lithium across regimens could refine therapeutic monitoring and guide choices that might mitigate long-term adverse effects.Methods: In this cross-sectional imaging study, 41 euthymic individuals with bipolar disorder receiving stable lithium carbonate treatment (20 once-daily, 21 twice-daily) underwent three consecutive 7Li-MRI scans and matched serum sampling over a 10-hour period (08:00, 14:00, and 18:00h). Whole brain lithium measurements across time points were compared according to regimen. Secondary analyses modelled tissue-specific profiles and examined the relationship between serum and brain lithium concentration using repeated measures ANOVA, linear mixed-effects models and population pharmacokinetics.Findings: At 12-hours post-dose (08:00h), brain lithium signal intensity and serum concentrations were equivalent across regimens. However, brain and serum lithium profiles differed over the daytime sampling period: once-daily dosing yielded declining serum and brain levels, while twice-daily dosing produced an inverted U-shaped serum and brain profile. Brain lithium signal intensity was higher in white matter than grey matter in both regimens and brain–serum ratios indicated more rapid equilibration in grey matter and cerebrospinal fluid compared to white matter. Interpretation: Brain lithium levels followed serum concentrations closely across the day, but aligned between regimens at the standard 12-hour post-dose sampling time point. These findings directly inform the ongoing discussion about the applicability of a common reference range across regimens. The difference in brain and serum profiles of lithium with once- and twice-daily dosing may inform regimen selection and therapeutic monitoring strategies in clinical practice.
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Mechanochemistry
- Vol. 3 (5) , 661-667
Identifying new solid forms of a labile pharmaceutical compound by additive assisted mechanochemistry
Ascorbic acid-assisted mechanochemistry enables the discovery and stabilisation of new cysteamine solid forms.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Mechanochemistry
- Vol. 3 (5) , 661-667
Open AccessIdentifying new solid forms of a labile pharmaceutical compound by additive assisted mechanochemistry
Ascorbic acid-assisted mechanochemistry enables the discovery and stabilisation of new cysteamine solid forms.
- Open Access
- 14 November 2025
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 218, 114933
A strategy to prevent ciprofloxacin induced corneal toxicity
- 14 November 2025
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 218, 114933
Open AccessA strategy to prevent ciprofloxacin induced corneal toxicity
- Open Access
- 7 November 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 216, 107367
An aciclovir intermediate can prevent drug-induced acute kidney injury
- 7 November 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 216, 107367
Open AccessAn aciclovir intermediate can prevent drug-induced acute kidney injury